Skip to main content
. 2022 Jul 27:10.1002/ijc.34209. Online ahead of print. doi: 10.1002/ijc.34209

FIGURE 1.

FIGURE 1

Total anti‐RBD anti‐SARS‐CoV‐2 spike receptor‐binding domain antibodies responses after mRNA vaccination. (A) Anti‐RBD antibody response were measured prior mRNA vaccination as a baseline, next 2‐5 weeks after second and 12 weeks second dose in multiple myeloma (MM) patients and (B) chronic lymphocytic leukemia (CLL). (C) Significantly higher response rates in MM patients in comparison with CLL measured 2‐5 weeks after second as well as 12 weeks after second dose evaluated by ELISA. (D) Differences in OD values between patients with the presence of anti‐RBD antibodies before vaccination (C+) and without (C−) in MM and CLL (E) in two‐time points after second vaccine dose. (F) Effect of antileukemic treatment in CLL patients without anti‐RBD antibodies before vaccination on antibody response, data for MM not showed due to an insufficient number of untreated patients. OD values were obtained with absorbance measured at 450 nm. The nonparametric two‐sided Mann‐Whitney U‐test was performed for pairwise comparisons of distributions between groups, P < .05 was considered as statistically significant [Color figure can be viewed at wileyonlinelibrary.com]